Clinical Biochemistry: Renal Function and Pathophysiology

Anatomy and Structural Organization of the Kidney

• Macroscopic Anatomy:     * Renal Capsule: The outer protective covering of the kidney.     * Renal Hilus: The depression where the renal artery, renal vein, and ureter enter/exit the organ.     * Renal Cortex: The outer region of the kidney tissue.     * Renal Medulla: The inner region of the kidney tissue, containing the renal pyramids.     * Renal Pelvis: The central collecting region that leads to the ureter.     * Blood Supply: Includes the interlobular artery and interlobular vein.

• The Nephron (Functional Unit):     * Renal Corpuscle: Comprised of the Glomerulus (a capillary bed network) and the Bowman’s Capsule.     * Arterioles: Blood enters via the Afferent arteriole and exits via the Efferent arteriole.     * Tubular System:         * Proximal Convoluted Tubule (PCT): Located in the cortex; features a brush border for absorption.         * Loop of Henle: Consists of a descending limb and an ascending limb extending into the medulla.         * Distal Convoluted Tubule (DCT): Located in the cortex.         * Collecting Duct: Leads to the renal pelvis.     * Associated Structures:         * Vasa Recta: Capillary loops supplying the loop of Henle.         * Juxtaglomerular Apparatus (JGA): Includes Macula densa cells (monitoring salt) and Juxtaglomerular cells (secreting renin).         * Podocytes: Specialized cells with foot processes that wrap around glomerular capillaries to form filtration slits.

Glomerular Filtration Rate (GFR)

• Blood Flow Dynamics:     * Renal blood flow accounts for approximately $25\%$ of cardiac output, totaling roughly $1200\,ml/minute$.     * Renal plasma flow is approximately $660\,ml/minute$.     * Filtration rate: Approximately $120\,ml/min$ is filtered into the nephron.     * Excretion rate: Approximately $1.2\,ml/min$ is excreted as urine, representing only $1\%$ of the filtered load.

• Determinants of GFR:     1. Renal blood flow and renal perfusion pressure.     2. The hydrostatic pressure difference between the tubule and the capillaries.     3. The total surface area available for ultrafiltration.

Tubular Function: Reabsorption and Secretion

• Reabsorption (Retention):     * Substances reclaimed from the filtrate include glucose, phosphate, amino acids, potassium, and peptides.     * The PCT is the primary site for reabsorbing glucose, amino acids, vitamins, $Na^{+}Cl^{-}$, and $H_{2}O$.     * The Loop of Henle creates an increasing ionic gradient in interstitial fluid; the descending limb is permeable to $H_{2}O$, while the ascending limb involves active transport of $Cl^{-}$ and $Na^{+}$.     * The Collecting Duct facilitates final water reabsorption and urea recycling.

• Secretion (Excretion):     * Substances added to the filtrate include various ions ($H^{+}$, $K^{+}$), ammonia ($NH_{3}$), drugs, toxins, and acids.

• Monitoring Tubular Function:     * There is no direct equivalent to GFR for tubular function; clinicians typically use Urine Osmolality as a proxy.

Physiological and Endocrine Roles of the Kidney

• Regulation: Maintains balance for fluids, electrolytes, and acid-base status through filtration, secretion, and reabsorption.

• Excretion: Removes metabolic waste products such as urea and creatinine, alongside various toxic molecules.

• Endocrine Functions:     * Vitamin D Activation: Critical for calcium regulation.     * Erythropoietin (EPO): Stimulates red blood cell production.     * Renin: Produced in the afferent arteriole; essential for water and electrolyte homeostasis via the RAA system.

Fluid Compartments and Terminology

• Total Body Water: Approximately $42\,L$ in an average adult.     * Intracellular Fluid (ICF): $2/3$ of total ($~28\,L$).     * Extracellular Fluid (ECF): $1/3$ of total ($~14\,L$).

• Clinical Implications of Imbalance:     * Reduced ICF leads to lethargy, confusion, and coma.     * Blood loss (ECF reduction) leads to reduced circulation, renal shutdown, and shock.

• Key Definitions:     * Concentration: Ratio of mass to volume.     * Osmolality: Total concentration of all solutes ($mmol/kg$). Normal serum osmolality is approximately $285\,mmol/kg$. It can be approximated as $2 \times [Na^{+}]$ (unless glucose or urea are elevated).     * Oncotic Pressure: Osmotic pressure in capillaries (difference between serum and ICF), primarily determined by albumin protein concentration.

Intravenous (IV) Treatment Distribution

• Theoretical Distribution of 1 Litre Infusions:     * 5% Glucose (Dextrose): Distributes across all compartments. Approximately $94\,ml$ remains in plasma, $180\,ml$ in interstitial fluid, and $820\,ml$ enters ICF.     * 0.9% Saline (Isotonic): Remains largely in the extracellular space. Approximately $180\,ml$ in plasma and $820\,ml$ in interstitial fluid; $0\,ml$ enters ICF.     * Colloid: Stays entirely within the plasma volume ($1000\,ml$).

• Fluid Electrolyte Compositions ($mmol/L$):     * Sweat: $Na^{+} (50)$, $K^{+} (5)$, $Cl^{-} (40)$, $HCO_{3}^{-} (0)$.     * Gastric: $Na^{+} (20-100)$, $K^{+} (5-10)$, $Cl^{-} (120-160)$, $HCO_{3}^{-} (0)$.     * Bile: $Na^{+} (150)$, $K^{+} (5-10)$, $Cl^{-} (40-80)$, $HCO_{3}^{-} (20-40)$.     * Ileal: $Na^{+} (140)$, $K^{+} (5)$, $Cl^{-} (105)$, $HCO_{3}^{-} (40)$.

Water and Electrolyte Balance Regulation

• Arginine Vasopressin (AVP/ADH): Secreted by the brain to regulate water homeostasis.

• Renin-Angiotensin-Aldosterone (RAA) System:     * Triggered by sympathetic stimulation, decreased pressure, or decreased sodium delivery to the distal tubule.     * Renin (Kidney) converts Angiotensinogen (Liver) to Angiotensin I.     * ACE (Angiotensin Converting Enzyme) converts Angiotensin I to Angiotensin II.     * Angiotensin II causes vasoconstriction (increasing SVR) and triggers Aldosterone release from the adrenal cortex.     * Aldosterone promotes sodium and water retention.

• Natriuretic Peptides: Mediate endocrine effects through the kidney to reduce blood volume.

Clinical Presentation of Renal Disease

• Symptomatic:     * Frank haematuria (blood in urine).     * Proteinuria (frothy urine) and ankle swelling.     * Uraemic Symptoms: Nausea, vomiting, anorexia, weight loss, malaise, generalized pruritus (itching), hiccoughs, and chest pain (uraemic pericarditis).

• Asymptomatic:     * Hypertension.     * Abnormal blood screening results.     * Dipstick abnormalities (incidental finding).     * Abnormal renal imaging.

• Clinical Challenges:     * Primary Care: Distinguishing Chronic Renal Failure (CRF) from the natural GFR decline associated with aging.     * Acute Care: Detecting Acute Kidney Injury (AKI), characterized by a rapid decline in GFR.

Urine Analysis and Volume

• Volume Standards:     * Normal Adult: $1.5$ to $2.5\,litres/day$.     * Polyuria: Frequent passage of large volumes.     * Oliguria: Defined as <1\,ml/kg/h (infants), <0.5\,ml/kg/h (children), or <400-500\,ml/24h (adults, which is $~17-21\,ml/hour$).     * Anuria: Complete failure to produce urine.

• Dipstick Parameters: Detects protein, blood, nitrites/leucocyte esterase (infection indicators), and glucose.

• Specimen Types:     * Spot urine.     * Timed collection (24-hour or overnight).     * First morning collection.     * Correction using Albumin/Creatinine Ratio (ACR) to account for concentration variations.

Laboratory Protein and Albumin Methods

• Total Protein Measurement: Dye or precipitation-based methods including Sulphosalicylic acid, Pyrogallol red, and Benzethonium chloride.

• Urine Albumin: Formerly called "microalbumin."     * Essential for monitoring diabetic patients for renal impairment.     * Measured via immunoturbidimetry.     * Subject to substantial intraindividual variation (day vs. night; resting vs. activity).

Glomerular Function Assessment: Creatinine

• Dynamics: Anhydride of creatine formed in muscle from creatine phosphate. Production is constant within an individual but varies between individuals based on muscle mass. It is cleared by kidneys; impairment leads to elevated serum levels.

• Analytical Methods:     1. Jaffe Method (1894): Colorimetric using alkaline picric acid at $505\,nm$. Low cost (<1p/test) but non-specific; subject to interference from bilirubin, protein, ascorbate, ketones, and uric acid.     2. Enzymatic Method: More specific ($10p$/test). Creatinine is converted by creatinine deiminase to ammonia, eventually monitoring $NADH$ to $NADP$ change at $340\,nm$.

• Serum Reference Intervals (Adults):     * Males ($\ge 20\,yrs$): $64-104\,\mu mol/L$ ($0.7-1.2\,mg/dL$).     * Females ($\ge 20\,yrs$): $49-90\,\mu mol/L$.

Clearance and eGFR Formulas

• Creatinine Clearance Rate (CCR):     $\text{CCR} = \frac{\text{Urine Concentration} \times \text{Urine Volume (ml)}}{\text{Plasma Concentration} \times \text{Time (min)}}$     * $1440\,minutes$ is used for 24-hour collections.

• MDRD (Modification of Diet in Renal Disease):     * Four-variable version: Plasma creatinine, age, gender, and ethnicity.     * $\text{eGFR (ml/min/1.73 m}^{2}\text{)} = [186 \times (\text{p.creat}/88.4)] - (1.154 \times \text{age})^{-0.203} (\times 0.742 \text{ if female}) (\times 1.210 \text{ if Afro-American})$

• CKD-EPI (2009 & 2021):     * Now recommended by NICE as it is more accurate than MDRD, especially in the physiological/mild disease range (>60\,ml/min).     * 2021 "Ethnicity-neutral" Equation:         \text{eGFRcr} = 142 \times \min(\text{Scr/\kappa}, 1)^{\alpha} \times \max(\text{Scr/\kappa}, 1)^{-1.200} \times 0.9938^{\text{Age}} \times 1.012 [\text{if female}]         * $\text{Scr}$ is in $mg/dl$ (Multiply $\mu mol/l$ by $0.0113$).         * $\kappa = 0.7$ (females) or $0.9$ (males).         * $\alpha = -0.241$ (females) or $-0.302$ (males).

Chronic Kidney Disease (CKD) Staging

Urea and Cystatin C

• Urea:     * Product of protein catabolism (deamination of amino acids).     * Affected by protein intake; less sensitive than creatinine.     * Reference Range: $2.5-10.7\,mmol/L$ ($7-30\,mg/dL\,BUN$).     * Method: Urease/Glutamate dehydrogenase reaction monitored at $340\,nm$.

• Cystatin C:     * $13\,kD$ protease inhibitor produced by all nucleated cells.     * Independent of muscle mass and sex.     * Proposed as a more sensitive marker for slight to moderately decreased GFR.

Exogenous Markers

• Inulin: Fructose polymer; gold standard but difficult to measure.

• Radioactive Markers: $^{51}Cr\text{-EDTA}$ and $^{99m}Tc\text{-DTPA}$. Reliable but restricted in children/pregnancy.

• Iohexol: A non-radioactive contrast agent measured via HPLC or UPLC. Baseline and samples at $120$, $180$, and $240\,minutes$ are required to calculate clearance.

Electrolyte Abnormalities

• Sodium ($Na^{+}$):     * Hyponatraemia (Low Na): Water retention (SIAD), GI loss, aldosterone deficiency. Symptoms: Skin tenting, postural blood pressure drop, dry mucous membranes.     * Hypernatraemia (High Na): Water loss (sweat, Diabetes insipidus), increased intake (salt poisoning if >180\,mmol/l).

• Potassium ($K^{+}$):     * Hypokalaemia: Reduced intake, vomiting, insulin treatment, Refeeding syndrome (rapid drops in $Mg$, $K$, and phosphate).     * Hyperkalaemia: Severe if >7.0\,mmol/l (risk of cardiac arrest). Causes include renal failure, metabolic acidosis (K released from cells), insulin deficiency, ACE inhibitors, or ARBs.

• Measurement: Ion-selective electrodes (ISE) using potentiometry to measure the EMF between reference and sensor electrodes ($Ag/AgCl$).

Acute Kidney Injury (AKI)

• Epidemiology: Affects $13\%-18\%$ of hospital admissions; mortality >20\%.

• Classification:     * Pre-renal: Reduced blood supply (burns, blood loss, heart failure, GI loss).     * Renal: Direct kidney damage or disease.     * Post-renal: Blockage reducing filtration pressure (stones, cancer).

• NICE AKI Staging Criteria:     * Stage 1: Creatinine rise $\ge 1.5\times$ baseline (within 7 days), or rise of >26\,\mu mol/L (within 48h), or urine output <0.5\,ml/kg/h for $6-12h$.     * Stage 2: Rise $\ge 2\times$ baseline or urine output <0.5\,ml/kg/h for $\ge 12h$.     * Stage 3: Rise $\ge 3\times$ baseline, or rise to >354\,\mu mol/L, or urine output <0.3\,ml/kg/h for $\ge 24h$, or anuria for $\ge 12h$.

• Newer Markers: NGAL, KIM-1, Cystatin C.

pH Disorders

• Acidemia: Decreased arterial pH.     * Respiratory Acidosis: Increased $PaCO_{2}$.     * Metabolic Acidosis: Decreased $[HCO_{3}^{-}]$.

• Alkalemia: Increased arterial pH.     * Respiratory Alkalosis: Decreased $PaCO_{2}$.     * Metabolic Alkalosis: Increased $[HCO_{3}^{-}]$.